Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Human Health HoldingsHKSE:01419 +1.36%58 Return-on-Tangible-Equity is 5.37% as of Dec. 2025, which is 50% below its 10-year median of 10.80. GuruFocus rates HKSE:01419 with a GF Score™ of 58/100 and a GF Value™ of HK$0.81 (Fairly Valued). The stock has 3 warning signs investors should review. Among 577 Healthcare Providers & Services companies, Human Health Holdings ranks worse than 67.07% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Human Health Holdings's annualized net income for the quarter that ended in Dec. 2025 was HK$37.8 Mil. Human Health Holdings's average shareholder tangible equity for the quarter that ended in Dec. 2025 was HK$703.8 Mil. Therefore, Human Health Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 5.37%.
The historical rank and industry rank for Human Health Holdings's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01419'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -16.48 Med: 10.8 Max: 69.77
Current: 3.97
During the past 13 years, Human Health Holdings's highest Return-on-Tangible-Equity was 69.77%. The lowest was -16.48%. And the median was 10.80%.
HKSE:01419's Return-on-Tangible-Equity is ranked worse than 67.07% of 577
companies
in the Healthcare Providers & Services industry
Industry Median: 10.62
vs HKSE:01419: 3.97
Human Health Holdings (HKSE:01419) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Human Health Holdings Return-on-Tangible-Equity Related Terms
Human Health Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Human Health Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Health Holdings Return-on-Tangible-Equity Chart
HKSE:01419 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Human Health Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Health Holdings Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Human Health Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Human Health Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 5.37% mean?
Human Health Holdings (HKSE:01419) has a Return-on-Tangible-Equity of 5.37% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Human Health Holdings and its competitors. This is 50% below median its historical median of 10.80. According to the industry distribution chart, Human Health Holdings ranks #387 out of 577 companies in the Healthcare Providers & Services industry, placing it in the top 67.1%.
Is Human Health Holdings' Return-on-Tangible-Equity too high?
Human Health Holdings' current Return-on-Tangible-Equity of 5.37% is 50% below median its 10-year median of 10.80. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.62. Human Health Holdings' value of 5.37% is 49.4% below this industry median. Based on the distribution chart, Human Health Holdings ranks #387 out of 577 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Human Health Holdings has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Human Health Holdings' Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Human Health Holdings ranks #387 out of 577 companies for Return-on-Tangible-Equity. This places Human Health Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.62. Human Health Holdings' value of 5.37% is 49.4% below this benchmark. While the company's 10-year median is 10.80 vs. the industry median of 10.62, Human Health Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.62, based on 577 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Health Holdings's current Return-on-Tangible-Equity of 5.37% is 49.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Human Health Holdings and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Health Holdings's current Return-on-Tangible-Equity is 5.37%, which is 50% below median its own 10-year median of 10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Health Holdings stock overvalued right now?
Based on GuruFocus' analysis, Human Health Holdings (HKSE:01419) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.81, compared to a current price of HK$0.75 — trading 8% below its estimated fair value. The current Return-on-Tangible-Equity is 5.37%, which is 50% below median its 10-year median of 10.80 and 49.4% below the Healthcare Providers & Services industry median of 10.62. Human Health Holdings' overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Human Health Holdings (HKSE:01419), the current Return-on-Tangible-Equity is 5.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Health Holdings (HKSE:01419) Overvalued in 2026?
Based on GuruFocus' analysis, Human Health Holdings stock appears to be undervalued.
The current stock price of HK$0.75 is trading 8% below its estimated GF Value™ of HK$0.81.
GuruFocus considers Human Health Holdings to be Fairly Valued.
Key valuation signals for HKSE:01419:
Return-on-Tangible-Equity: 5.37% (50% below median its 10-year median of 10.80)
GF Value™: HK$0.81 vs. price of HK$0.75 (8% below fair value)
Industry Position: 49.4% below the Healthcare Providers & Services median (#387 of 577)
No single metric tells the full story. See the HKSE:01419 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Health Holdings Ltd is engaged in the provision of healthcare services. The company segments include general practice services, specialties services, and dental services. It offers general practice services, including general consultation, diagnostics, and preventative health, minor procedure, vaccination, physical check-up, health education, occupational health advisory, Cardiology, Dental Implant, Urology, work injury assessment services, Orthodontics and others. It generates maximum revenue from the general practice services segment.
58GF Score
Get the complete analysis for HKSE:01419
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01419 has been successfully added to your 
